AMRN, Initiating as an Outperform - ANCHORING a Foot hold in the Dyslipidemia Market
Amarin Corp. (AMRN)’s lead product AMR101 (omega fatty acid – no DHA) has blockbuster potential being the best-in-class drug vs. approved drugs to treat hypertriglyceridemia. AMRN intends to file the NDA for hypertriglyceridemia – (TG level: ≥500 mg/dL) in 3Q11 and other indications next year. We expect partnership/acquisition by ….. For more detail, please read our report released on July 5, 2011, titled – “ANCHORING a Foot hold in the Dyslipidemia Market”."
COMPANIES MENTIONED
Amarin Corporation
Amarin Corporation
